CASE REPORT


Bridging with Tirofiban During Temporary Withdrawal of Oral Antiplatelets for Two Major Surgical Procedures in High Ischaemic Risk Patients



Maria Vlachou, Matthaios Didagelos, Antonios Kouparanis, Haralambos Karvounis, Antonios Ziakas*
Ist Cardiology Department, AHEPA General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece


Article Metrics

CrossRef Citations:
1
Total Statistics:

Full-Text HTML Views: 2685
Abstract HTML Views: 679
PDF Downloads: 441
ePub Downloads: 279
Total Views/Downloads: 4084
Unique Statistics:

Full-Text HTML Views: 1343
Abstract HTML Views: 404
PDF Downloads: 357
ePub Downloads: 212
Total Views/Downloads: 2316



Creative Commons License
© 2019 Vlachou et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Ist Cardiology Department, AHEPA General Hospital, Aristotle University of Thessaloniki, Greece, St. Kyriakidi 1, P.C. 54636, Thessaloniki, Greece; Tel: +306942488823; Fax: +302310994837; E-mail: manthosdid@yahoo.gr


Abstract

Background:

Recent coronary stent implantation requires Dual Antiplatelet Therapy (DAPT) for at least 6 months. Serious issues are raised when non-cardiac surgery is required during this period, because of the balance between ischemic and haemorrhagic complications.

Case Reports:

We report 2 high ischemic risk cases requiring intermediate bleeding risk non-cardiac surgery, during the first month of DAPT initiation. Perioperative management with discontinuation of the P2Y12 inhibitor and bridging with tirofiban, while aspirin was uninterrupted, was uneventful.

Conclusion:

Bridging with intravenous glycoprotein IIb/IIIa receptor inhibitors may be a safe and effective alternative to P2Y12 inhibitor discontinuation in non-deferrable non-cardiac surgery.

Keywords: Tirofiban, Dual antiplatelet therapy, Acute coronary syndrome, Cardiac ischemic complications, Pre and Post-procedural bleeding.